Katarina Maloney is a biotech executive with extensive experience in business and product development, operational and marketing strategy, supply chain management, and international and domestic production and distribution. She has substantial expertise in launching startups and directing expansion for profitable growth in the health, wellness and technology industries. Katarina values building rapport and sustaining professional relationships to encourage optimal business solutions. Katarina Maloney is currently serving as CEO of IQMIND.ai. Under her leadership, IQMIND.ai is transforming the landscape of mental health and brain performance by integrating advanced QEEG brain mapping, EEG technology, and neuro-optimization solutions. The company is focused on providing accessible, data-driven approaches to mental health, helping individuals manage conditions such as PTSD, anxiety, depression, addiction, and TBI. Maloney is dedicated to expanding IQMIND.ai’s reach through strategic partnerships, cutting-edge technology, and scalable solutions that empower individuals to achieve mental clarity and cognitive well-being.
Katarina, your work has taken you to new areas in recent years. Right now, you are focusing on the mental health crisis in the United States. Start by telling us about why you are tackling this crisis.
This mission is deeply personal. Years ago, I suffered a traumatic brain injury that left me disoriented and lost within the medical system. I realized that even with access to high-quality care, the approach was reactive, fragmented, and symptom-focused. That experience changed the course of my life and inspired the creation of IQMIND—a company not just solving mental health issues but working to optimize the human brain itself.
What we’re building is more than therapy. It’s a scalable model for peak cognitive performance. Whether someone is recovering from trauma or training for elite competition, we believe the brain can be measured, strengthened, and optimized—just like a muscle.
How bad is the mental health crisis in the US and how has it reached this point?
We are facing a full-scale brain health emergency. The numbers are staggering—one in five adults in the U.S. experiences mental illness every year. Yet our system is still reliant on outdated, trial-and-error methods. Overmedication, lack of brain-based diagnostics, and stigma have created a dangerous gap between symptoms and solutions.
But we’re also seeing a turning point. The science is here. The tools exist. What we need now is the will to implement a brain-first, data-driven model across every level of care—from trauma recovery to athletic optimization.
Tell us more about IQMIND and its role in mental health.
IQMIND is a neuroscience and mental performance company focused on diagnosing and treating brain-based disorders using science-backed, non-invasive tools. We offer advanced 30 minutes AI brain assessments that allow us to map brain activity and uncover disruptions in function. From there, we use customized brain tune-up protocol sessions to help the brain self-regulate and heal.
But we don’t stop at treatment—we also focus on brain optimization, helping high performers like athletes, students, and executives sharpen focus, and increase reaction time. Our platform integrates clinical research, FDA-cleared technology, and AI-based diagnostics to deliver outcomes that traditional therapy often can’t do alone.
How is technology able to explore brain disorders to help with mental health issues?
The brain is an electro- chemical system. With tools like qEEG and ERP, we can map its function in real time and detect disruptions in key areas related to mood, cognition, and performance. We treat it like any other system—assess it, target the dysfunction, and implement a protocol to restore balance.
Whether someone is struggling with PTSD or training for the NFL, our technology gives us insight into their neural performance and allows us to guide them toward specific, measurable improvement.
The use of AI is increasing every day. It is being used in various industries including the medical field. How is AI changing the way mental health is treated?
AI is one of our greatest allies in mental health. At IQMIND, we use AI to analyze thousands of brain scans and compare them to massive neuroimaging databases, identifying patterns and abnormalities much faster than a human clinician ever could. This allows us to make highly personalized treatment decisions, reduce trial and error, and ensure progress is monitored with precision.
AI is the breakthrough we’ve been waiting for. At IQMIND, we feed brainwave data into proprietary AI algorithms that compare each brain against a vast neurobiological database. This lets us pinpoint abnormalities and develop truly customized protocols.
Beyond that, AI allows us to do something revolutionary: track brain optimization in real time. For our ProSports division, this is especially powerful. Coaches and doctors can now see cognitive fatigue, concussion risk, and focus metrics live—on the sideline.
What specifically can AI do to help treat patients?
AI empowers us in several critical ways:
- It delivers precision diagnostics, revealing subtle dysfunctions invisible to the naked eye.
- It designs personalized brain training for each unique profile, increasing outcomes and reducing recovery time.
- It enables real-time performance tracking, so both patients and clinicians can see brain changes over time.
In our ProSports Fan Engagement and In Venue Gaming applications, AI also will enhance fan engagement and predictive analytics—allowing teams to make data-driven decisions and even helping fans interact with live game data through our patented motion tracking and sentiment systems.
How can IQMIND improve the quality of mental and physical healthcare patients receive?
IQMIND is building the future of brain optimization. Our core technologies combine qEEG brain mapping, ERP testing, and AI-based analysis to evaluate how the brain functions in real time. Within 20 minutes, we can pinpoint underperforming regions and tailor treatment accordingly.
But we’re more than diagnostics—we’re building a full ecosystem. Our PEAK Performance clinics will offer cognitive tune-ups and personalized brain training that help athletes reduce anxiety, improve reaction time and focus, regulate mood, and enhance performance overall.
And through our ProSports division, we’ve extended that mission to athletes, teams and fans. We are developing wearable tech, real-time motion tracking, and brainwave analytics that help athletes optimize performance while reducing injury risk. This technology is already being used to train elite teams and is redefining what it means to be game-ready—mentally and physically.
Is the medical industry changing for the better or is it going backwards rather than forwards?
It’s evolving, but slowly. While we’ve seen incredible progress in areas like cancer and heart disease, mental health still lags in innovation. Yet the tide is turning. More clinicians are embracing technology and patients are demanding better care. At IQMIND, we see ourselves as helping to lead that transformation by bringing advanced diagnostics and therapy tools into the mainstream, where they belong.
In our previous interview, we focused a lot of the talk on CBD. Is CBD still a major focus and is its popularity still growing?
CBD was part of my wellness journey, and it remains a helpful tool for certain conditions like anxiety and inflammation. But my current focus is far more advanced. With IQMIND, we’re not just soothing symptoms, we’re measuring and optimizing brainwave performance.
CBD may complement our protocols in some cases, but the future is in neurotechnology, data science, and AI. That’s where we’re making the biggest impact now.
Where will mental health treatment in the US be in the next five years?
Within five years, brain mapping will be as common as getting your blood pressure checked. Clinics and sports teams will use AI-powered dashboards to track cognitive performance. Schools will assess learning differences using real-time brain data. And fans in stadiums will engage with live game experiences that integrate athlete brain performance into the entertainment.
With IQMIND’s ProSports division, we’re already building this future. Our in-venue gaming system uses AI to drive fan predictions, trivia, and motion-based wagering—all tied to live player data. It creates a new layer of connection between teams, players, and fans—while monetizing engagement like never before.
Meanwhile, our helmet-integrated sensors will continue to make sports safer by monitoring cognitive load, preventing concussions, and optimizing training. We’re also exploring fan health integration, so spectators themselves can receive performance tips and wellness tracking while they cheer from the stands.
IQMIND isn’t just a healthcare company. It’s a performance technology platform for brains—and it’s changing the game for players, fans, and the future of mental health worldwide.
At IQMIND, we believe the brain is the final frontier of human performance. Whether it’s helping an NFL quarterback avoid injury, a veteran reclaim their focus, or a student unlock their potential, our mission is clear: empower the brain, and you empower the person. Brain optimization is no longer optional. It’s the future—and we’re building it now.
To learn more about Katarina Maloney and IQMIND, please visit https://iqmind.ai
